97 related articles for article (PubMed ID: 10786665)
21. [Raf kinase and its inhibitory regulators].
Guo YH; Chen GH; Tang CS
Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):255-8. PubMed ID: 14628476
[No Abstract] [Full Text] [Related]
22. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.
Hartmann F; Horak EM; Cho C; Lupu R; Bolen JB; Stetler-Stevenson MA; Pfreundschuh M; Waldmann TA; Horak ID
Int J Cancer; 1997 Jan; 70(2):221-9. PubMed ID: 9009164
[TBL] [Abstract][Full Text] [Related]
23. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
24. [Advances in antitumor activity of the hsp90 inhibitor geldanamycin].
Liao ZY; Zhen YS
Yao Xue Xue Bao; 2001 Sep; 36(9):716-20. PubMed ID: 12580116
[No Abstract] [Full Text] [Related]
25. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide.
Clevenger RC; Blagg BS
Org Lett; 2004 Nov; 6(24):4459-62. PubMed ID: 15548050
[TBL] [Abstract][Full Text] [Related]
27. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
Mandler R; Wu C; Sausville EA; Roettinger AJ; Newman DJ; Ho DK; King CR; Yang D; Lippman ME; Landolfi NF; Dadachova E; Brechbiel MW; Waldmann TA
J Natl Cancer Inst; 2000 Oct; 92(19):1573-81. PubMed ID: 11018093
[TBL] [Abstract][Full Text] [Related]
28. Use of an antibody to target geldanamycin.
Mendelsohn J
J Natl Cancer Inst; 2000 Oct; 92(19):1549-51. PubMed ID: 11018081
[No Abstract] [Full Text] [Related]
29. [Anticancer agents targeting oncogene products].
Uehara Y
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1885-91. PubMed ID: 8379683
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin.
Sugita T; Tanaka S; Murakami T; Miyoshi H; Ohnuki T
Biochem Mol Biol Int; 1999 Apr; 47(4):587-95. PubMed ID: 10319410
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
Schnur RC; Corman ML; Gallaschun RJ; Cooper BA; Dee MF; Doty JL; Muzzi ML; Moyer JD; DiOrio CI; Barbacci EG
J Med Chem; 1995 Sep; 38(19):3806-12. PubMed ID: 7562911
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
Citri A; Alroy I; Lavi S; Rubin C; Xu W; Grammatikakis N; Patterson C; Neckers L; Fry DW; Yarden Y
EMBO J; 2002 May; 21(10):2407-17. PubMed ID: 12006493
[TBL] [Abstract][Full Text] [Related]
33. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.
Schnur RC; Corman ML; Gallaschun RJ; Cooper BA; Dee MF; Doty JL; Muzzi ML; DiOrio CI; Barbacci EG; Miller PE
J Med Chem; 1995 Sep; 38(19):3813-20. PubMed ID: 7562912
[TBL] [Abstract][Full Text] [Related]
34. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.
Chiosis G; Timaul MN; Lucas B; Munster PN; Zheng FF; Sepp-Lorenzino L; Rosen N
Chem Biol; 2001 Mar; 8(3):289-99. PubMed ID: 11306353
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of geldanamycin-testosterone hybrids.
Kuduk SD; Harris TC; Zheng FF; Sepp-Lorenzino L; Ouerfelli Q; Rosen N; Danishefsky SJ
Bioorg Med Chem Lett; 2000 Jun; 10(11):1303-6. PubMed ID: 10866406
[TBL] [Abstract][Full Text] [Related]
36. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
Tikhomirov O; Carpenter G
J Biol Chem; 2000 Aug; 275(34):26625-31. PubMed ID: 10862618
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of geldanamycin-estradiol hybrids.
Kuduk SD; Zheng FF; Sepp-Lorenzino L; Rosen N; Danishefsky SJ
Bioorg Med Chem Lett; 1999 May; 9(9):1233-8. PubMed ID: 10340605
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
Mandler R; Dadachova E; Brechbiel JK; Waldmann TA; Brechbiel MW
Bioorg Med Chem Lett; 2000 May; 10(10):1025-8. PubMed ID: 10843208
[TBL] [Abstract][Full Text] [Related]
39. Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems.
Kasuya Y; Lu Z; Kopecková P; Kopecek J
Bioorg Med Chem Lett; 2001 Aug; 11(16):2089-91. PubMed ID: 11514145
[TBL] [Abstract][Full Text] [Related]
40. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.
Mandler R; Kobayashi H; Davis MY; Waldmann TA; Brechbiel MW
Bioconjug Chem; 2002; 13(4):786-91. PubMed ID: 12121134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
